CJC-1295 with DAC
Long-Acting GHRH Analog
CJC-1295 with DAC is a long-acting growth hormone-releasing hormone (GHRH) analog. The added Drug Affinity Complex (DAC) binds to serum albumin, dramatically extending the peptide's half-life and producing sustained elevations in GH and IGF-1.
The Science
What is CJC-1295 with DAC?
CJC-1295 is a modified analog of GHRH. The 'with DAC' version incorporates a Drug Affinity Complex—a lysine linker that binds covalently to serum albumin, extending half-life from minutes to roughly 8 days.
This sustained exposure produces continuous, low-amplitude elevations in growth hormone and IGF-1 rather than the pulsatile pattern produced by short-acting GHRH peptides.
It is most often paired with a GHRP/ghrelin mimetic (such as Ipamorelin) to amplify GH pulse amplitude on top of the elevated baseline.
Laboratory Observations
Key Observed Effects of CJC-1295 with DAC
Sustained GH/IGF-1
Provides continuous support for recovery, body composition, and tissue repair.
Recovery Support
Elevated IGF-1 promotes tissue repair and recovery.
Body Composition
Supports fat loss and lean mass when paired with training and nutrition.
Mechanism of Action
Mechanism of Action
DAC technology extends CJC-1295's half-life, producing sustained GHRH receptor activation.
Albumin Binding
DAC linker binds serum albumin, extending half-life to roughly 8 days.
Sustained GHRH Signaling
Produces continuous low-amplitude elevations in GH and IGF-1.
Synergy with GHRPs
Pairs effectively with ghrelin mimetics to amplify GH pulse amplitude.
Research-Only Notice
CJC-1295 with DAC is categorized by the FDA as for research-purposes-only. It is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease. The information above summarizes effects observed in laboratory studies to date and is provided strictly for scientific and educational reference.